Relationship between breast cancer and cardiac myxoma

..

Is Routine Diagnostic Radioiodine Whole-Body Scintigraphy Needed in Patients who Received Ablative doses of Radioiodine for Differentiated Thyroid Carcinoma?

Aim: The present large-series retrospective sought to assess DWBS findings 6‒12 weeks after RIAT in DTC patients in various risk groups. In addition, the study compared patients’ simultaneous sTg levels.Material and Methods: The follow-up data of 2879 patients who had received RIAT for DTC between 1998 and 2016 were evaluated for inclusion in the study. The study retrospectively evaluated the following: age at the time of diagnosis; gender; histopathological features of thyroidectomy materials (histological subtype, variant, dimension, multi-focality, thyroid capsule, and vascular invasion of tumors); TNM stage; ATA classification; sTg, suppressed-serum Tg, and antiTg antibody levels; and DWBS findings. Patients were categorized according to sTg level (undetectable, 1‒10 ng/ml, and >10 ng/ml). Then, the DWBS findings were analyzed according to sTg level.Results: The study analyzed 2184 patients (1805 F, 379 M; mean age: 43.54±12.64). In 2077 (95%) patients, the DWBSs performed 6‒12 months after RIAT had shown no pathological uptake throughout the entire body. Pathological uptake had been detected in the neck and outside the neck in 88 (4%) and 19 (1%) patients, respectively. All patients who had had normal DWBSs also had had undetectable simultaneous sTg levels. In addition, the DWBSs had been normal in 187 (8%) patients who had had simultaneous sTg levels> 1 ng/ml and in 286 (13%) patients who had had levels > 10 ng/ml. In all patients who had pathological uptake in DWBSs, simultaneous sTg levels were > 1ng/ml, and in 47, they were> 10 ng/ml.Conclusion: Routine DWBS seems to be unnecessary, even in high-risk DTCs. However, in patients who have detectable levels of serum sTg, it could be performed to localize the disease and plan patient management

Primer ve metastatik karaciğer tümörlü hastalarda transarteriyel radyoembolizasyon ve kemoembolizasyona erken yanıtı değerlendirmede18F-FLT PET/BT’nin rolü

Objectives: Metastases and primary malignancies are common in the liver. Local ablative applications such as transarterial chemoembolization (TACE), and transarterial radioembolization (TARE) provide minimally invasive and safe treatment in unresectable liver tumors. Early detection of response to treatment prevents unnecessary toxicity and cost in non-responder patients and provides an earlier use of other options that may be effective. This study aimed to identify the role of18F-fluorothymidine (FLT) positron emission tomography/computed tomography (PET/CT) in the assessment of early response to TACE and TARE treatments in patients with unresectable primary and metastatic liver tumors. Methods: This single-center study included 63 patients who underwent18F-FLT PET/CT for response evaluation after TACE and TARE. After excluding 20 patients whose data were missing 43 TARE-receiving patients were analyzed. The compatibility of change in semi-quantitative values obtained from the18F-FLT PET/CT images with the treatment responses detected in18F-fluorodeoxyglucose PET/CT, CT, and MR images and survival was evaluated. Results: There was no correlation between early metabolic, morphological response, and18F-FLT uptake pattern, and change in standardized uptake values (SUV) which were ΔSUVmax, ΔSUVmean, ΔSUVpeak., ΔSUVmean, ΔSUVpeak values. There was no significant correlation between18F-FLT uptake pattern, ΔSUVmax, ΔSUVmean, ΔSUVpeak, and overall survival, progression-free survival (PFS) for the target lobe PFS for the whole-body. The survival distributions for the patients with >30% change in ΔSUVmax and ΔSUVpeak values were statistically significantly longer than the patients with <30% change (p<0.009 and p<0.024, respectively). Conclusion: There was significant longer PFS for target liver lobe in patients with more than 30% decrease in18F-FLT SUVmax and SUVpeak of the liver lesion in primary and metastatic unresectable liver tumors undergoing TARE